




## Directorate General of Drug Administration of Bangladesh

Memo No: \_\_\_\_\_

Date: 

**Namtest**

**31 Feld street**

Attention: \_\_\_\_\_ (e.g. Regulatory Affairs Manager)

**Subject: REVIEW DEFICIENCY LETTER**

Application Reference Number: 0018/09/2016

In response to your application number mentioned above related to the Registration/Marketing Authorization of the following product, you are requested to provide response or submit the necessary document(s) to the following deficiency(ies) in order to complete the dossier evaluation process.

Trade name	<u>ATV</u>
Generic name(s)	<u>ATAZANAVIR</u>
Strength(s) per dosage unit	<u>300 mg</u>
Dosage form	<u>TABLET</u>

See below or the attached file(s) for the list of deficiency(ies) to be addressed.

**No PIL provided**

**The outer and inner labels are missing**

**Product quality information not provided**

The review of the application will commence again once you submit your responses. If you have any queries as to the meaning of this letter, you should contact the undersigned immediately.

Yours faithfully

**Director General,  
Directorate General of Drug Administration  
&  
Licencing Authority (Drugs)  
Government of the People's Republic of Bangladesh**